Business Description
Akero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00973Y1082
Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.73 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -3.5 | |||||
| 3-Year EPS without NRI Growth Rate | -4.7 | |||||
| 3-Year FCF Growth Rate | -7 | |||||
| 3-Year Book Growth Rate | 8.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -17.88 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.52 | |||||
| 9-Day RSI | 38.78 | |||||
| 14-Day RSI | 42.23 | |||||
| 6-1 Month Momentum % | 41.3 | |||||
| 12-1 Month Momentum % | 54.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.25 | |||||
| Quick Ratio | 17.25 | |||||
| Cash Ratio | 16.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.1 | |||||
| Shareholder Yield % | -18.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -33.88 | |||||
| ROA % | -31.13 | |||||
| ROIC % | -518.35 | |||||
| ROC (Joel Greenblatt) % | -24195.45 | |||||
| ROCE % | -31.83 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.69 | |||||
| Price-to-Tangible-Book | 2.69 | |||||
| EV-to-EBIT | -5.58 | |||||
| EV-to-Forward-EBIT | -4.55 | |||||
| EV-to-EBITDA | -5.58 | |||||
| EV-to-Forward-EBITDA | -4.64 | |||||
| EV-to-FCF | -6.14 | |||||
| Price-to-Net-Current-Asset-Value | 2.98 | |||||
| Price-to-Net-Cash | 3.11 | |||||
| Earnings Yield (Greenblatt) % | -17.92 | |||||
| FCF Yield % | -10.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akero Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.461 | ||
| Beta | 0.12 | ||
| Volatility % | 60.25 | ||
| 14-Day RSI | 42.23 | ||
| 14-Day ATR (€) | 0.699964 | ||
| 20-Day SMA (€) | 28.479 | ||
| 12-1 Month Momentum % | 54.8 | ||
| 52-Week Range (€) | 16.4 - 36 | ||
| Shares Outstanding (Mil) | 69.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akero Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akero Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akero Therapeutics Inc Frequently Asked Questions
What is Akero Therapeutics Inc(STU:0K4)'s stock price today?
The current price of STU:0K4 is €27.21. The 52 week high of STU:0K4 is €36.00 and 52 week low is €16.40.
When is next earnings date of Akero Therapeutics Inc(STU:0K4)?
The next earnings date of Akero Therapeutics Inc(STU:0K4) is 2025-02-28 Est..
Does Akero Therapeutics Inc(STU:0K4) pay dividends? If so, how much?
Akero Therapeutics Inc(STU:0K4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers